2013
Breast cancer presentation and diagnostic delays in young women
Ruddy KJ, Gelber S, Tamimi RM, Schapira L, Come SE, Meyer ME, Winer EP, Partridge AH. Breast cancer presentation and diagnostic delays in young women. Cancer 2013, 120: 20-25. PMID: 24347383, DOI: 10.1002/cncr.28287.Peer-Reviewed Original ResearchConceptsCare delaysSymptoms of cancerBreast cancerFirst visitYoung womenMulticenter cohort studyMedical record reviewPatient's first visitBreast cancer presentationBreast abnormalitiesFirst signOwn breast cancerHealth care providersMost young womenPoor financial statusCancer presentationCohort studyDiagnostic delayRecord reviewTumor characteristicsPoor outcomeSystemic symptomsDisease stageEligible participantsExamination abnormalities
2006
Study participants’ perceptions of the process and impact of receiving results of N9831
Partridge A, Wolff A, Marcom P, Kaufman P, Moore C, Lake D, Fleming G, Rugo H, Collyar D, Winer E. Study participants’ perceptions of the process and impact of receiving results of N9831. Journal Of Clinical Oncology 2006, 24: 518-518. DOI: 10.1200/jco.2006.24.18_suppl.518.Peer-Reviewed Original ResearchTrial participantsLarge cooperative group trialsPhase III trialsCooperative group trialsSubset of womenClinical trial participantsHealth care providersAdjuvant chemotherapyRecurrent diseaseIII trialsMultivariable analysisClinical trialsBreast cancerGroup trialsCare providersAverage ageFavorable responseClinical investigatorsPsychosocial supportPatientsWomenSubstantial proportionTrialsStudy resultsGreater satisfaction
2002
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. Journal Of Clinical Oncology 2002, 20: 3317-27. PMID: 12149306, DOI: 10.1200/jco.2002.06.020.Peer-Reviewed Original ResearchConceptsHormone receptor-positive breast cancerReceptor-positive breast cancerAromatase inhibitorsBreast cancerASCO Health Services Research CommitteeAdjuvant breast cancer settingClinical Oncology technology assessmentEvidence-based technology assessmentsHealth Services Research CommitteeBreast cancer-specific survivalAdjuvant hormonal therapyBreast cancer settingCancer-specific survivalBreast cancer incidenceIndividual health care providersHealth care providersAmerican SocietyOutcomes of interestNet health benefitAdjuvant tamoxifenASCO panelAdjuvant therapyHormonal therapyOverall survivalStandard therapy
1993
Silicone Controversy: a Survey of Women With Breast Cancer and Silicone Implants
Winer EP, Fee-Fulkerson K, Fulkerson CC, Catoe G, Georgiade KE, Conaway M, Brunatti C, Holmes V, Rimer BK. Silicone Controversy: a Survey of Women With Breast Cancer and Silicone Implants. Journal Of The National Cancer Institute 1993, 85: 1407-1411. PMID: 8350364, DOI: 10.1093/jnci/85.17.1407.Peer-Reviewed Original ResearchConceptsBreast cancerBreast reconstructionMajority of womenSilicone implantsSilicone breast implantsMedical complicationsBreast implantsSuch womenPossible medical complicationsHealth care providersPotential medical complicationsSurvey of womenReconstruction patientsTreatment optionsPossible complicationsPatient concernsReconstructive surgeryCare providersBreast implant devicesComplicationsPermanent prosthesisStudy participantsCancerSubstantial riskPlastic surgeons